Cervicovaginal levels of lactoferrin, secretory leukocyte protease inhibitor, and RANTES and the effects of coexisting vaginoses in human immunodeficiency virus (HIV)-seronegative women with a high risk of heterosexual acquisition of HIV infection.
Innate immune factors in mucosal secretions may influence human immunodeficiency virus type 1 (HIV-1) transmission. This study examined the levels of three such factors, genital tract lactoferrin [Lf], secretory leukocyte protease inhibitor [SLPI], and RANTES, in women at risk for acquiring HIV infection, as well as cofactors that may be associated with their presence. Women at high risk for HIV infection meeting established criteria (n = 62) and low-risk controls (n = 33) underwent cervicovaginal lavage (CVL), and the CVL fluid samples were assayed for Lf and SLPI. Subsets of 26 and 10 samples, respectively, were assayed for RANTES. Coexisting sexually transmitted infections and vaginoses were also assessed, and detailed behavioral information was collected. Lf levels were higher in high-risk (mean, 204 ng/ml) versus low-risk (mean, 160 ng/ml, P = 0.007) women, but SLPI levels did not differ, and RANTES levels were higher in only the highest-risk subset. Lf was positively associated only with the presence of leukocytes in the CVL fluid (P < 0.0001). SLPI levels were lower in women with bacterial vaginosis [BV] than in those without BV (P = 0.04). Treatment of BV reduced RANTES levels (P = 0.05). The influence, if any, of these three cofactors on HIV transmission in women cannot be determined from this study. The higher Lf concentrations observed in high-risk women were strongly associated with the presence of leukocytes, suggesting a leukocyte source and consistent with greater genital tract inflammation in the high-risk group. Reduced SLPI levels during BV infection are consistent with an increased risk of HIV infection, which has been associated with BV. However, the increased RANTES levels in a higher-risk subset of high-risk women were reduced after BV treatment.
Novak
Richard M
RM
University of Illinois at Chicago, 808 S. Wood St., M/C 735, Rm. 888, Chicago, IL 60612, USA. rmnovak@uic.edu
Donoval
Betty A
BA
Graham
Parrie J
PJ
Boksa
Lucy A
LA
Spear
Gregory
G
Hershow
Ronald C
RC
Chen
Hua Yun
HY
Landay
Alan
A
D000293:Adolescent; D000328:Adult; D002584:Cervix Uteri / Q000276:immunology* / Q000378:metabolism; D018946:Chemokine CCL5 / Q000276:immunology; D015331:Cohort Studies; D005260:Female; D015658:HIV Infections / Q000276:immunology* / Q000635:transmission; D018023:HIV Seronegativity / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D020010:Heterosexuality; D006801:Humans; D007113:Immunity, Innate / Q000276:immunology; D007781:Lactoferrin / Q000276:immunology; D012309:Risk-Taking; D053481:Secretory Leukocyte Peptidase Inhibitor / Q000378:metabolism; D047568:Unsafe Sex; D044364:Vaginal Douching; D016585:Vaginosis, Bacterial / Q000276:immunology* / Q000382:microbiology / Q000821:virology
D018946:Chemokine CCL5; D053481:Secretory Leukocyte Peptidase Inhibitor; D007781:Lactoferrin